ARCT - Arcturus Therapeutics Holdings Inc logo

Arcturus Therapeutics Holdings Inc

ARCT

Arcturus Therapeutics develops messenger RNA medicines, focusing on therapeutics for rare liver and respiratory diseases, including cystic fibrosis and OTC deficiency. It also creates mRNA vaccines for COVID-19 and seasonal influenza.

โš•๏ธ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 10 years ago โ†’$447today

Score Overview

1 Year
Score
Net Growth-41.79%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-64.59%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score4.3
Net Growth54.20%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth92.58%
Rev Trend20%
Revenue Consistencyโ€”
All Time
Score
Net Growth-29.28%
Net Trend33%
Net Income Consistency
Rev Growth149.51%
Rev Trend33%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Arcturus Therapeutics Holdings Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ARCT does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 14.46โ€”
1 Year2025-09-26
$ 22.17-34.78%
5 Years2021-09-28
$ 47.91-69.82%
10 Years2016-09-28
$ 32.34-55.29%
All Time2020-04-16
$ 17.00-14.94%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 23M-$ 93M$ 191M
2025$ 67M-$ 65M$ 230M
2024$ 138M-$ 80M$ 237M
2023$ 157M-$ 29M$ 292M
2022$ 205M$ 9M$ 391M
2021$ 12M-$ 203M$ 370M
IPO2020$ 9M-$ 72M$ 462M
ARCT - Arcturus Therapeutics Holdings Inc logo

Arcturus Therapeutics Holdings Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 9M to $ 67M and net income went from -$ 72M to -$ 65M. Revenue increased in 1 of those 5 years; net income in 2.

Arcturus Therapeutics Holdings Inc currently holds a 5-year HDB Score of 4.3 out of 10. How the HDB Score is calculated.

Membership

Explore ARCT with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies